搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 30 天
时间不限
过去 1 小时
过去 24 小时
过去 7 天
按相关度排序
按时间排序
17 小时
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction ...
On Monday, GSK plc (NYSE:GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the ...
23 小时
GSK Says Potential Blockbuster Helps Treat Common Nasal Disease
GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...
4 天
GSK shares jump on $2.2 billion Zantac settlement
GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits ...
pharmaphorum
20 小时
GSK asthma hope depemokimab works in second indication
Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...
MyChesCo on MSN
6 小时
GSK’s AREXVY Vaccine Shows Promising Results Across Three RSV Seasons
GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...
ENDPOINTS NEWS
13 小时
Two GSK trials with long-acting drug in chronic rhinosinusitis hit prima ...
GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...
BioPharma Dive
13 小时
GSK says antibody drug succeeds in testing for chronic nasal condition
The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.
5 天
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...
6 天
GSK RSV shot 43% effective against severe disease in third year
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
4 天
on MSN
GSK to Pay Over $2 Billion in Bid to End Most U.S. Zantac Lawsuits
GSK agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its ...
4 天
on MSN
GSK Rises After Settling Zantac Cases for Up to $2.2 Billion
GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court ...
FiercePharma
6 天
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈